Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. - Wikidata - thesis-toulmin - TriplyDB

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

http://www.wikidata.org/entity/Q35759403

about

Does HAART efficacy translate to effectiveness? Evidence for a trial effect Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV A combination drug of abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDS The HIV antiretroviral drug efavirenz has LSD-like properties Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials The renaissance of fixed dose combinations: Combivir Illustration of a measure to combine viral suppression and viral rebound in studies of HIV therapy Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure Monitoring HIV viral load in resource limited settings: still a matter of debate?A strategy to model nonmonotonic dose-response curve and estimate IC50 CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany.PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG).Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy.Efavirenz in the therapy of HIV infection.Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.HIV/AIDS, undernutrition, and food insecurity Abacavir/lamivudine combination in the treatment of HIV: a review.Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects.Predicted Interval Plots (PIPS): A Graphical Tool for Data Monitoring of Clinical Trials In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir HIV infection.Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count.Antiretroviral therapy: current drugs The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.

P2860

Q21135313-671DADD5-5AED-498C-93E2-18C19166AA32 Q21144607-1B944270-D293-4A2E-A15E-0FF18FE16C3D Q24200188-DEF8115A-D0A5-4BD0-888C-658ABB252364 Q24202180-4B80B47A-4E93-4B94-89B2-2039E4CC5D77 Q24239831-594CB8A5-B5A9-4A02-B2B3-A42DD7164DF2 Q24608183-8A15A9FB-B28E-42AF-AAAF-C2F6DD899AB0 Q24628212-6E9DE965-2ED1-442A-A1A1-7196E741ED0B Q27003431-39F08F8B-E015-4243-9FDE-CEDE949CA417 Q27015850-DA4F060B-40BF-403A-AF3A-CCEC2D8EB5B6 Q28081266-1D4BDFEB-D43A-4EDE-B9AB-46EE48E380B3 Q28279752-A86B5510-B891-4630-B5B9-839C5377267E Q28385909-FBA0E730-4627-408B-B5D7-21A0F21E61BB Q28476822-E92375B7-195F-4970-8F0C-BCE8F864A4F4 Q28478779-2BAE6B2A-A15D-4769-B9C2-0858BC1095EE Q28485511-874CE7E1-256C-4B6E-9563-0A289F93E8D9 Q28535044-45B87544-CB96-4FC8-BB49-FAA3C8F90661 Q30438405-9A64E115-F05C-47BF-A226-F5CD457C6BB3 Q30655744-B5CE343D-36F8-45D3-A9FD-FFE16634DFB6 Q30834094-3587A983-1B42-4C28-B205-7E1F3D284DE2 Q30925594-3F3EB310-6259-46A6-AA31-5CD82278522A Q31037300-04913E28-3138-4914-8C83-8422607C4BD5 Q33436334-297F741F-0024-4977-83B5-A5C70C4D303B Q33507274-226D20BE-E87F-4A3C-B55B-05D3F6352FA5 Q33607011-E0570689-AD41-491B-8C65-372DC90E0607 Q33649563-2D427E80-AAB9-431F-A853-6775F889332B Q33672541-63FA8A50-1AAA-4333-9B78-688F46CD0EE1 Q33681279-A7071911-9018-47CB-B2CD-AE492191C344 Q33701378-AB4860D1-E872-4B72-BA71-4222FEF3E530 Q33715435-ED8EB3C5-D9E1-4BC7-94E3-5B6A72C45668 Q33803473-F9A128F1-68B9-4F6A-9E36-A5D6CC269343 Q33806497-3F297A2D-DAA8-4E8C-9708-30A9574A8FFE Q33851739-B94491E8-BB3D-4516-B51D-7ED49B10752C Q33857855-C1AE7E73-7972-49EB-A5BC-A8ED7A1285AD Q33872810-35CCF146-3312-40A6-A244-9F641D64636C Q33959260-ED5B306F-DA37-4BB7-B50D-C1FEC7D0E043 Q33985702-BAB557DE-66A3-423C-ABE3-3435281E2FFB Q34011172-BF93250C-BBDF-4464-9121-6E5CC3B7E8F2 Q34056936-31C16C25-A442-4807-8452-A55264BF8764 Q34085926-37720341-F05F-4464-9852-97E0739B2654 Q34102246-CBAF5EDE-35AA-4731-BBCC-BFBE2CF66511

P2860

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

http://www.wikidata.org/entity/Q35759403

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Triple-nucleoside regimens ver ...... treatment of HIV-1 infection.

@ast

Triple-nucleoside regimens ver ...... treatment of HIV-1 infection.

@en

type

label

Triple-nucleoside regimens ver ...... treatment of HIV-1 infection.

@ast

Triple-nucleoside regimens ver ...... treatment of HIV-1 infection.

@en

prefLabel

Triple-nucleoside regimens ver ...... treatment of HIV-1 infection.

@ast

Triple-nucleoside regimens ver ...... treatment of HIV-1 infection.

@en

P1433

Q35759403-05B78F57-526D-4CC0-A4E9-CE7A314BAEAD

P1476

Q35759403-A2D77C75-7850-4734-8ACC-483753210F40

P2093

Q35759403-2407653E-302B-4947-890E-68086F733EB2

Q35759403-4C46754B-87FD-456E-97F2-A8F058F0F206

Q35759403-4D3D44E6-B158-45D7-BACB-7DA699E48563

Q35759403-51093909-96BD-4CCD-97C3-76E09F759F03

Q35759403-59B4359B-FA3D-499E-B209-8F7291760F16

Q35759403-6AD86DEB-6D2D-4CE2-B7E5-0AEB1AF94437

Q35759403-6FA614B6-AA2D-4224-B1B9-D9FC00AFA5A4

Q35759403-8422F8A2-9EDD-4B7F-893A-D3ADE8DE0103

Q35759403-85E5A75B-BBAA-4B55-A3E7-7EAECD8D70E9

Q35759403-89FF89FD-57C0-4CF4-91CE-346D6CE2523D

P304

Q35759403-AC6D2C18-A872-4AB3-8BE4-E71F47A88AD6

P31

Q35759403-4EBF6195-8912-4938-98B0-55C53EC8BF2E

P356

Q35759403-D5530A18-CACE-4BF6-B1FA-1909C6BEA070

P407

Q35759403-DF5FE1A8-8168-462F-9A9E-989AEC30AF3E

P433

Q35759403-A378B8C1-8CBD-42E3-96EA-7BFAE0E3FE54

P478

Q35759403-83FEACDB-8E07-4147-A77F-26C751A1A93A

P50

Q35759403-01AEAF54-D6A8-458F-91B7-E2863060FA60

P577

Q35759403-25F407EA-9FE2-466D-BE79-41FB55712A4F

P698

Q35759403-5798A600-CB7D-4482-A88E-AF3DE4C0238C

P356

P1433

The New England Journal of Medicine

P1476

Triple-nucleoside regimens ver ...... treatment of HIV-1 infection.

@en

P2093

AIDS Clinical Trials Group Study A5095 Team

http://www.w3.org/2001/XMLSchema#string

Bruce R Schackman

http://www.w3.org/2001/XMLSchema#string

Cecilia M Shikuma

http://www.w3.org/2001/XMLSchema#string

Christopher D Pilcher

http://www.w3.org/2001/XMLSchema#string

Daniel R Kuritzkes

http://www.w3.org/2001/XMLSchema#string

Edward P Acosta

http://www.w3.org/2001/XMLSchema#string

Heather J Ribaudo

http://www.w3.org/2001/XMLSchema#string

Karin L Klingman

http://www.w3.org/2001/XMLSchema#string

Kathleen E Squires

http://www.w3.org/2001/XMLSchema#string

Mallory D Witt

http://www.w3.org/2001/XMLSchema#string

P304

1850-1861

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA031772

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

350

http://www.w3.org/2001/XMLSchema#string

P50

Robert L. Murphy

P577

2004-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15115831

http://www.w3.org/2001/XMLSchema#string